Skip to main content

Chemical synthesis of a new drug family to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology

Project description

New drug to treat the deadliest cancer

Survival rates in most cancers have increased in recent years, but brain cancers in adults and children continue to represent high mortality rates. Gliomas constitute 60 % of all brain tumours, and glioblastoma multiforme (GBM) is considered the deadliest and largely incurable cancer. Researchers on the EU-funded chemGLIO project have discovered a new family of compounds that are cytotoxic to cancer cells and particularly effective against GBM, resulting in the development of the GLIX1 drug. Based on preclinical studies where the drug showed total elimination of GBM tumour mass in 50 % of mice and tumour regression in all mice, the project aims to develop GLIX1 to reach human clinical trials and ultimately approval for clinical use.

Call for proposal

H2020-INNOSUP-2018-2020

See other projects for this call

Sub call

H2020-INNOSUP-2020-02

Coordinator

HEMISPHERIAN AS
Net EU contribution
€ 119 035,00
Address
Gaustadalleen 21
0349 Oslo
Norway

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
No data